• Je něco špatně v tomto záznamu ?

Vitamin D: A key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants

H. Sabit, S. Abdel-Ghany, MS. Abdallah, O. Abul-Maaty, AI. Khoder, NA. Shoman, MS. Farrag, P. Martasek, AM. Noreddin, M. Nazih

. 2024 ; 32 (6) : 3631-3652. [pub] 20241016

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003218

As of the 7th of July 2024, 775,754,322 confirmed cases of COVID-19, including 7,053,902 deaths worldwide, had been reported to the WHO (World Health Organization). Nevertheless, untill the 15th of July 2024, a total of 13,578,710,228 vaccine doses had been administered, with almost no country spared from COVID-19 attacks. The pathophysiology of this virus is complicated, and several symptoms require a deep understanding of the actual mechanisms. It is unclear why some patients develop severe symptoms while others do not, although literature suggests a role for vitamin D. Vitamin D plays a crucial role in the infection or in ameliorating the severity of symptoms. The mechanism of action of vitamin D and vitamin D deficiency (VDD) is well understood. VDD is associated with increased hospitalization of severely ill patients and increased levels of COVID-19-caused mortality. Recent studies suggest that vitamin D levels and genetic variations in the vitamin D receptor (VDR) gene significantly impact the severity and outcomes of COVID-19, especially in the infections caused by Delta and Omicron variants. Furthermore, VDD causes immune system dysregulation upon infection with SARS-CoV-2, indicating that vitamin D sufficiency is crucial in fighting against COVID-19 infection. The therapeutic effect of vitamin D raises interest in its potential role as a prophylactic and treatment adjunct. We evaluate the immunomodulatory effects of vitamin D and its ability to enhance the efficacy of new antiviral drugs like molnupiravir and paxlovid against SARS-CoV-2. This review discusses the role of vitamin D sufficiency and VDD in COVID-19 initiation and progression, emphasizing the molecular mechanisms by which vitamin D exerts its actions as a proactive step for the next pandemic. However, there is still no clear evidence of vitamin D's impact on prevention and treatment, leading to contradictory findings. Therefore, large-scale randomized trials are required to reach a definitive conclusion. A bibliometric analysis of publications related to vitamin D, immunity, and COVID-19 revealed a significant increase in research activity in this area, particularly in 2020-2024, underscoring the growing recognition of vitamin D's potential role in the context of the pandemic.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003218
003      
CZ-PrNML
005      
20250206104156.0
007      
ta
008      
250121s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10787-024-01578-w $2 doi
035    __
$a (PubMed)39406981
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Sabit, Hussein $u Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P. O. Box 77, Giza, Egypt. hussein.sabit@must.edu.eg
245    10
$a Vitamin D: A key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants / $c H. Sabit, S. Abdel-Ghany, MS. Abdallah, O. Abul-Maaty, AI. Khoder, NA. Shoman, MS. Farrag, P. Martasek, AM. Noreddin, M. Nazih
520    9_
$a As of the 7th of July 2024, 775,754,322 confirmed cases of COVID-19, including 7,053,902 deaths worldwide, had been reported to the WHO (World Health Organization). Nevertheless, untill the 15th of July 2024, a total of 13,578,710,228 vaccine doses had been administered, with almost no country spared from COVID-19 attacks. The pathophysiology of this virus is complicated, and several symptoms require a deep understanding of the actual mechanisms. It is unclear why some patients develop severe symptoms while others do not, although literature suggests a role for vitamin D. Vitamin D plays a crucial role in the infection or in ameliorating the severity of symptoms. The mechanism of action of vitamin D and vitamin D deficiency (VDD) is well understood. VDD is associated with increased hospitalization of severely ill patients and increased levels of COVID-19-caused mortality. Recent studies suggest that vitamin D levels and genetic variations in the vitamin D receptor (VDR) gene significantly impact the severity and outcomes of COVID-19, especially in the infections caused by Delta and Omicron variants. Furthermore, VDD causes immune system dysregulation upon infection with SARS-CoV-2, indicating that vitamin D sufficiency is crucial in fighting against COVID-19 infection. The therapeutic effect of vitamin D raises interest in its potential role as a prophylactic and treatment adjunct. We evaluate the immunomodulatory effects of vitamin D and its ability to enhance the efficacy of new antiviral drugs like molnupiravir and paxlovid against SARS-CoV-2. This review discusses the role of vitamin D sufficiency and VDD in COVID-19 initiation and progression, emphasizing the molecular mechanisms by which vitamin D exerts its actions as a proactive step for the next pandemic. However, there is still no clear evidence of vitamin D's impact on prevention and treatment, leading to contradictory findings. Therefore, large-scale randomized trials are required to reach a definitive conclusion. A bibliometric analysis of publications related to vitamin D, immunity, and COVID-19 revealed a significant increase in research activity in this area, particularly in 2020-2024, underscoring the growing recognition of vitamin D's potential role in the context of the pandemic.
650    _2
$a lidé $7 D006801
650    12
$a COVID-19 $x imunologie $7 D000086382
650    12
$a vitamin D $x terapeutické užití $x aplikace a dávkování $7 D014807
650    12
$a nedostatek vitaminu D $x farmakoterapie $x imunologie $7 D014808
650    _2
$a pandemie $7 D058873
650    _2
$a SARS-CoV-2 $x imunologie $7 D000086402
650    _2
$a receptory kalcitriolu $x metabolismus $7 D018167
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Abdel-Ghany, Shaimaa $u Department of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, P. O. Box 77, Giza, Egypt
700    1_
$a Abdallah, Mahmoud S $u Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, 32897, Egypt $u Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, 21110, Jordan
700    1_
$a Abul-Maaty, Osama $u Faculty of Science, Mansoura University, Mansoura, Egypt
700    1_
$a Khoder, Ahmed I $u Scientific Office, Egyptian Society of Pharmacogenomics and Personalized Medicine (ESPM), Cairo, Egypt $u Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Egypt $u Pharmacology and Toxicology Department, Faculty of Pharmacy, Menoufia University, Shebin El-Koum, Egypt
700    1_
$a Shoman, Nabil A $u Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt
700    1_
$a Farrag, Mohamed Sameh $u Scientific Office, Egyptian Society of Pharmacogenomics and Personalized Medicine (ESPM), Cairo, Egypt $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague Ke Karlovu 2, 128 08, Praha 2, Czech Republic
700    1_
$a Martasek, Pavel $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague Ke Karlovu 2, 128 08, Praha 2, Czech Republic
700    1_
$a Noreddin, Ayman M $u Scientific Office, Egyptian Society of Pharmacogenomics and Personalized Medicine (ESPM), Cairo, Egypt $u Department of Clinical Pharmacy, Faculty of Pharmacy, Ahram Canadian University (ACU), 6th of October City, Giza, 12566, Egypt $u Department of Internal Medicine, School of Medicine, University of California-Irvine, Irvine, CA, USA
700    1_
$a Nazih, Mahmoud $u Scientific Office, Egyptian Society of Pharmacogenomics and Personalized Medicine (ESPM), Cairo, Egypt. Mahmoud.Nazih5698@pharm.aun.edu.eg $u Department of Clinical Pharmacy, Faculty of Pharmacy, Ahram Canadian University (ACU), 6th of October City, Giza, 12566, Egypt. Mahmoud.Nazih5698@pharm.aun.edu.eg $u Al Ryada University for Science and Technology (RST), ElMehwar ElMarkazy-2, Cairo - Alex desert RD K92, Sadat City, 16504, Egypt. Mahmoud.Nazih5698@pharm.aun.edu.eg $1 https://orcid.org/000900000522399X
773    0_
$w MED00002244 $t Inflammopharmacology $x 1568-5608 $g Roč. 32, č. 6 (2024), s. 3631-3652
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39406981 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104152 $b ABA008
999    __
$a ok $b bmc $g 2263146 $s 1239225
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 32 $c 6 $d 3631-3652 $e 20241016 $i 1568-5608 $m Inflammopharmacology $n Inflammopharmacology $x MED00002244
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace